Publication Name	World Journal of Gastroenterology
Manuscript ID	7490
Country	Spain

Received	2013-11-22 07:11
Peer-Review Started	2013-11-22 11:18
To Make the First Decision	2014-01-09 16:21
Return for Revision	2014-01-12 17:51
Revised	2014-02-13 02:42
Second Decision	2014-03-19 13:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-03-19 14:58
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-05-09 10:37
Publish the Manuscript Online	2014-05-28 11:45

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Manuscript Source	Invited Manuscript
All Author List	Carlos Aguado, Beatriz García-Paredes, Miguel Jhonatan Sotelo, Javier Sastre and Eduardo Díaz-Rubio
Funding Agency and Grant Number
Corresponding Author	Eduardo Díaz-Rubio, MD, PhD, Department of Medical Oncology, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Martín Lagos, s/n, 28040 Madrid, Spain. ediazrubio.hcsc@salud.madrid.org
Key Words	Capecitabine; 5-Fluorouracil; Metastatic colorectal cancer
Core Tip	Although there is still controversy about whether capecitabine-based regimes can replace 5-fluorouracil (5-FU) in clinical practice in the treatment of first-line metastatic colon cancer, we have reviewed most of different randomized studies and meta-analyses, and we can conclude that capecitabine appear to be an effective, safe, convenient, and economically viable alternative to 5-FU.
Publish Date	2014-05-28 11:45
Citation	Aguado C, García-Paredes B, Sotelo MJ, Sastre J, Díaz-Rubio E. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? World J Gastroenterol 2014; 20(20): 6092-6101
URL	http://www.wjgnet.com/1007-9327/full/v20/i20/6092.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i20.6092

Full Article (PDF)	WJG-20-6092.pdf
Full Article (Word)	WJG-20-6092.doc
Manuscript File	7490-Review.doc
Answering Reviewers	7490-Answering reviewers.PDF
Copyright License Agreement	7490-Copyright assignment.PDF
Non-Native Speakers of English Editing Certificate	7490-Language certificate.pdf
Peer-review Report	7490-Peer review(s).pdf
Scientific Editor Work List	7490-Scientific editor work list.doc